Rigel Pharmaceuticals is a clinical-stage drug development company that focuses on discovering and developing small-molecule drugs for the treatment of inflammatory/autoimmune diseases, certain cancers, and metabolic diseases. The company's research centers around intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel Pharmaceuticals has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia, and asthma, as well as in cancer. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca, which has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Rigel Pharmaceuticals is dedicated to discovering, developing, and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases.